In vivo最新文献

{"title":"Endotoxin Activity Assay as a Novel Predictor of Disease Progression in Patients With Mild Cholangitis.","authors":"Koichi Mori, Kentaro Miyake, Ryusei Matsuyama, Koki Goto, Sayaka Arisaka, Yusuke Suwa, Toshiaki Kadokura, Yuki Homma, Itaru Endo","doi":"10.21873/invivo.13970","DOIUrl":"https://doi.org/10.21873/invivo.13970","url":null,"abstract":"<p><strong>Background/aim: </strong>Acute cholangitis is a critical biliary infection that can swiftly evolve into sepsis and organ failure. Certain patients with mild acute cholangitis might advance to a more severe status. Identifying predictive factors for such exacerbation is of paramount importance. This study aimed to investigate whether the endotoxin activity assay (EAA) could serve as a predictive biomarker for the progression of mild acute cholangitis.</p><p><strong>Patients and methods: </strong>We conducted a retrospective observational study at Yokohama City University Hospital, enrolling 200 patients hospitalized with acute cholangitis between May 2011 and June 2015. Patients with initially mild acute cholangitis were stratified into two groups based on their severity on Day 1: the stable group (remaining mild) and the exacerbation group (progressing to moderate/severe cholangitis). Clinical parameters were analyzed to assess risk factors for exacerbation.</p><p><strong>Results: </strong>Among 74 patients with mild acute cholangitis at admission, 33 (44.6%) progressed to moderate/severe cholangitis within 24 h. Multivariate logistic regression analysis identified chemotherapy within 28 days [odds ratio (OR)=3.440, 95% confidence interval (CI)=1.170-10.100, <i>p</i>=0.025], serum albumin levels (OR=0.303, 95%CI=0.094-0.975, <i>p</i>=0.045), and EAA ≥0.4 (OR=3.880, 95%CI=1.210-12.500, <i>p</i>=0.023) as independent predictors of disease exacerbation. A predictive equation was developed using the logistic regression model: log (P/1-P)=3.285-1.265×Alb (mg/dl) + 1.291 × (Chemotherapy within 28 days) +1.343 × (EAA ≥0.4) (P: the probability of exacerbation).</p><p><strong>Conclusion: </strong>EAA was identified as the most significant factor for exacerbating mild acute cholangitis. The combination of EAA, albumin levels, and a history of chemotherapy within the past 28 days suggests the potential to predict the progression of mild acute cholangitis to a more severe form.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1685-1693"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IgA Nephropathy Associated With Infliximab Treatment in Patients With Crohn's Disease: Study of IgA1 and IgA2 Expression in Glomeruli.","authors":"Akira Mima, Takahiro Nakamoto, Takamasa Matsuki, Suguru Kido, Yuta Saito, Takaaki Morikawa, Keishi Matsumoto, Hidemasa Gotoda, Shinji Lee","doi":"10.21873/invivo.13975","DOIUrl":"https://doi.org/10.21873/invivo.13975","url":null,"abstract":"<p><strong>Background/aim: </strong>It is well known that infliximab is an anti-tumor necrosis factor chimeric factor that is effective in treating inflammatory bowel diseases, such as Crohn's disease. Recently, there have been reports of new onset or flare-ups of immunoglobulin A (IgA) nephropathy during infliximab therapy for Crohn's disease. Inflammatory bowel disease-associated IgA nephropathy has been associated with IgA2; However, its activation by infliximab is still unknown.</p><p><strong>Case report: </strong>We report our experience with two patients who experienced acute exacerbations of pre-existing abnormal urinalysis and renal dysfunction 1-18 years following infliximab treatment for Crohn's disease. Renal biopsies at the time of renal disease flare-up revealed IgA nephropathy in one patient and mesangial proliferative nephropathy in the other. Immunostaining results showed no clear predominance of intraglomerular expression of IgA2, and the patient diagnosed with IgA nephropathy entered remission with high dose methylprednisolone pulse therapy and oral corticosteroids, without the need for tonsillectomy. In contrast, the patient with mesangial proliferative nephritis had many devastated glomeruli, thus corticosteroids were not administrated, and the patient was followed up.</p><p><strong>Conclusion: </strong>The clinical course of our patients, along with similar cases reported in the literature, indicates that infliximab therapy for Crohn's disease is linked to a relatively high risk of new-onset IgA nephropathy or disease relapse. This report is notable because it is the first to compare the expression of IgA1 and IgA2 in glomeruli in nephritis associated with infliximab therapy.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1731-1738"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Probiotic Supplementation on Body Fat, Skeletal Muscle Mass, and Body Mass Index in Individuals ≥45 Years Old: A Systematic Review.","authors":"Jessica Gutiérrez-Nájera, Víctor Manuel Mendoza-Núñez","doi":"10.21873/invivo.13927","DOIUrl":"https://doi.org/10.21873/invivo.13927","url":null,"abstract":"<p><strong>Background/aim: </strong>Probiotics are living microorganisms that confer health benefits when administered in adequate amounts. Several studies have shown the positive effects on body fat, muscle mass, and body mass index (BMI) in young adults and athletes; however, the results in adults aged ≥45 years are not conclusive.</p><p><strong>Materials and methods: </strong>A systematic review was conducted in accordance with the PRISMA guidelines, analyzing studies up to December 10, 2024, from nine databases (PubMed, Scopus, Web of Science, LILACS, SciELO, Springer, Redalyc, Cochrane Library and TESIUNAM). Mean differences (MD) were estimated using RevMan V 5.4.1. software.</p><p><strong>Results: </strong>Six hundred and sixty-six studies were identified, of which 15 met the eligibility criteria. A statistically significant decrease in fat mass (%) was found in two studies and in fat mass (kg) in another two studies. Likewise, one study reported a statistically significant increase in skeletal muscle mass.</p><p><strong>Conclusion: </strong>Probiotic supplementation may have a beneficial effect on reducing body fat mass and increasing or preventing skeletal muscle mass loss in adults ≥45 years old; however, further clinical trials are needed to determine the optimal types, doses, and duration of probiotic treatment for best results.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1220-1236"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of Galectin 3 and Activating Transcription Factor 3 in Nigral Dopaminergic Neurons of 6-Hydroxydopamine Induced Parkinsonian Rat Model.","authors":"Eun-Jin Lee, Yoon-Jung Choy, Ran-Sook Woo, Tai-Kyoung Baik, Hong-Il Yoo, Dae-Yong Song","doi":"10.21873/invivo.13938","DOIUrl":"https://doi.org/10.21873/invivo.13938","url":null,"abstract":"<p><strong>Background/aim: </strong>Parkinson's disease (PD) is an age-related neurodegenerative disease marked by the relatively progressive dopaminergic neuronal loss in the substantia nigra (SN). Retrograde degeneration of the nigrostriatal dopaminergic neurons by 6-hydroxydopamine (6-OHDA) has been widely used as a PD animal model, while endogenous 6-OHDA promotes the progression of PD pathology. Galectin 3 (Gal3) and activating transcription factor 3 (ATF3) have been implicated in neurodegenerative processes. The aim of this study was to investigate the expression pattern and roles of Gal3 and ATF3 in a Parkinson's disease animal model induced by 6-OHDA.</p><p><strong>Materials and methods: </strong>We investigated temporal and spatial profiles of Gal3 expression in 6-OHDA rat model of PD. Lesions were induced by unilateral stereotactic injections of 6-OHDA into the striatum. Three days prior to 6-OHDA lesion, Fluorogold (FG) was injected at the same coordinates as the subsequent 6-OHDA injection. 6-OHDA induced retrograde degeneration of tyrosine hydroxylase immunopositive and FG immunopositive neurons within SN in a time-dependent manner.</p><p><strong>Results: </strong>Activating transcription factor 3 (ATF3) expression was also upregulated in the SN, in a pattern similar to that of Gal3 immunoreactivity. Finally, we confirmed through triple immunofluorescence staining that ATF3 and Gal3 were colocalized in the dopaminergic neurons labeled with FG. These neurons were damaged by 6-OHDA.</p><p><strong>Conclusion: </strong>Gal3 may play a key role in the signaling pathway of dopaminergic neuronal cell death induced by 6-OHDA. This is the first <i>in vivo</i> demonstration that Gal3 is expressed in dopaminergic neurons injured by 6-OHDA.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1341-1354"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methotrexate Enhances Atherosclerosis Progression <i>via</i> Impairment of Folate Pathway in a Microminipig Model.","authors":"Yuko Onishi, Naoki Miura, Akihide Tanimoto, Hiroaki Kawaguchi","doi":"10.21873/invivo.13930","DOIUrl":"https://doi.org/10.21873/invivo.13930","url":null,"abstract":"<p><strong>Background/aim: </strong>As the pathophysiology of Microminipigs (μMPs) is similar to that of human, μMPs are useful in atherosclerosis research. To clarify the effect of methotrexate (MTX) on atherosclerosis, we investigated the pathology of MTX-induced atherosclerosis lesion exacerbation in μMPs fed a high-fat and high-cholesterol diet (HFHCD).</p><p><strong>Materials and methods: </strong>The μMPs were divided into four groups: HFHCD, HFHCD+MTX, HFHCD+MTX+leucovorin (LV), and HFHCD+MTX+folic acid (FA), and fed for two weeks. Laboratory tests including blood lipid, FA, and homocysteine (Hcy) levels, and pathological evaluation of the atherosclerosis lesion area and thickness were performed. Hepatic and jejunal gene expressions related to lipid and folate metabolism pathways including 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR) were monitored using RT-PCR.</p><p><strong>Results: </strong>The HFHCD+MTX group showed increased blood Hcy (<i>p</i><0.01) and decreased FA levels (<i>p</i><0.05) in accordance with increased hepatic MTR mRNA expression (<i>p</i><0.1) and exacerbation of atherosclerosis (<i>p</i>=0.051 for lesion area and <i>p</i>=0.045 for lesion thickness) compared to the HFHCD group. Administration of LV or FA attenuated the MTX-induced increase in the Hcy level (<i>p</i><0.01), atherosclerosis lesion thickness (<i>p</i><0.1), and MTR mRNA expression (<i>p</i><0.1 in HFHCD+MTX <i>vs.</i> HFHCD+MTX+LV groups).</p><p><strong>Conclusion: </strong>MTX exacerbated HFHCD-induced atherosclerosis mediated through reduced blood FA and the subsequent increase of Hcy in μMPs, indicating that the μMP model may advance cardio-oncology research by providing useful experimental approaches. As MTX is administered for rheumatoid arthritis and malignant tumors in humans, atherosclerosis exacerbation should be acknowledged as a possible adverse effect of MTX treatment.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1262-1274"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immersive Virtual Reality for Reducing Intraoperative Pain: A Pilot Randomized Controlled Trial.","authors":"Teppei Kamada, Hironori Ohdaira, Ryosuke Nishie, Daisuke Yamagishi, Takashi Aida, Junji Takahashi, Eisaku Ito, Shunjin Ryu, Satoshi Narihiro, Reo Takizawa, Taigo Hata, Masashi Yoshida, Ken Eto, Makoto Sumi, Yutaka Suzuki","doi":"10.21873/invivo.13964","DOIUrl":"https://doi.org/10.21873/invivo.13964","url":null,"abstract":"<p><strong>Background/aim: </strong>In this study, we aimed to evaluate the effect of virtual reality (VR) therapy on pain, anxiety, and other outcomes in patients with cancer undergoing central venous (CV) port placement.</p><p><strong>Patients and methods: </strong>We conducted a single-center randomized controlled trial with 10 adults with cancer undergoing CV port placement. Participants were randomized into the VR group (n=5), which received VR therapy with the Therapeia VR system (xCura), or the control group (n=5), which underwent conventional procedures. The primary and secondary outcomes included intraoperative pain, intraoperative and postoperative anxiety, blood loss, operative time, sensation of obstruction, and patient and surgeon satisfaction.</p><p><strong>Results: </strong>No significant differences were found between the VR and control groups regarding operative time, blood loss, preoperative anxiety, obstruction sensation, or surgeon satisfaction. However, compared with the control group, the VR group showed markedly lower intraoperative pain (<i>p</i>=0.03), intraoperative/postoperative anxiety (<i>p</i>=0.04), and higher patient satisfaction (<i>p</i>=0.03).</p><p><strong>Conclusion: </strong>The use of immersive VR therapy during CV port placement significantly reduced intraoperative pain and anxiety and enhanced patient satisfaction. These findings indicated that VR therapy may be an effective nonpharmacological adjunct for improving patient experience during invasive procedures.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1638-1646"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Claudin 18.2 Expression in Gastric Tumors and Other Tumor Types With Gastric Epithelium-like Differentiation.","authors":"Moonsik Kim, Ha Young Woo, Jinhee Kim, An Na Seo","doi":"10.21873/invivo.13954","DOIUrl":"https://doi.org/10.21873/invivo.13954","url":null,"abstract":"<p><strong>Background/aim: </strong>Claudin 18.2 is an emerging biomarker for claudin 18.2-targeted therapy. We investigated claudin 18.2 expression in diverse tumor types.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed 67 gastric tumors (61 surgically resected and six biopsy specimens) and 73 other tumor types (69 resected and four biopsy specimens), including those from the pancreas, hepatobiliary system, lung, ovary, uterine cervix, and others. Claudin 18.2 expression and positivity (≥75% of tumor cells showing moderate to strong membranous staining) were assessed using claudin 18 immunostaining (clone 43-14A).</p><p><strong>Results: </strong>Claudin 18.2 positivity was found in 47.8% (32/67) of gastric tumor samples. Epstein-Barr virus-associated gastric cancer showed a higher frequency of positivity (6/7, 85.7%), although not statistically significantly (<i>p</i>=0.216). Among gastric tumors from patients with lymph node or distant metastasis (n=20), four (20.0%) exhibited discrepancies in claudin 18.2 positivity between the primary and its metastasis. In other tumor types, claudin 18.2 positivity was more frequent in those with gastric epithelium-like differentiation, including pancreatic tumors (2/9, 22.2%), hepatobiliary carcinoma (2/8, 25.0%), invasive mucinous lung adenocarcinoma (4/5, 80.0%), and mucinous ovarian tumor (5/5, 100.0%) than in those with other histology (<i>p</i><0.001). Interestingly, pancreatic tumors, potential candidates for claudin 18.2-targeted therapy, often exhibited reduced or lack of claudin 18.2 expression in the invasive component.</p><p><strong>Conclusion: </strong>Overall, claudin 18.2 positivity occurred primarily in a significant proportion of gastric tumors and other tumors with gastric epithelium-like differentiation. Evaluating claudin 18.2 expression in all such tumors can benefit patients by guiding targeted therapy. Additionally, claudin 18.2 immunostaining serves as a lineage marker for gastric origin or gastric-like differentiation.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1540-1553"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Early Recovery of Renal Function and Residual Renal Function After Robot-assisted Partial Nephrectomy.","authors":"Shunta Hori, Mitsuru Tomizawa, Kenta Onishi, Yosuke Morizawa, Daisuke Gotoh, Tomonori Nakahama, Yasushi Nakai, Makito Miyake, Tatsuo Yoneda, Nobumichi Tanaka, Kiyohide Fujimoto","doi":"10.21873/invivo.13955","DOIUrl":"https://doi.org/10.21873/invivo.13955","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to explore factors related to residual renal function in patients with small renal tumors treated with robot-assisted partial nephrectomy.</p><p><strong>Patients and methods: </strong>This retrospective study included 188 patients with two functioning kidneys who were diagnosed with localized renal tumors and underwent robot-assisted partial nephrectomy using the clamping technique. The residual renal function 12 months after the surgery was evaluated in two ways: >90% preservation of the estimated glomerular filtration rate and no stage progression of chronic kidney disease.</p><p><strong>Results: </strong>The median age, body mass index, and warm ischemic time were 68 years, 23.3 kg/m², and 19 min, respectively. Ten patients were diagnosed with positive surgical margins. Multivariate analysis revealed no significant preoperative factors, including renal function. Among surgical factors, warm ischemic time was an independent factor for chronic kidney disease progression, whereas it showed no significant association with the preservation of residual renal function (<i>p</i> =0.042 and p=0.14, respectively). Early recovery, defined as the difference in estimated glomerular filtration rate before and three months post-surgery, independently correlated with poor residual renal function preservation and chronic kidney disease progression (<i>p</i><0.0001 and <i>p</i><0.0001, respectively). Furthermore, no significant difference was observed in residual renal function recovery between warm ischemic time <25 and ≥25 min (<i>p</i>=0.58).</p><p><strong>Conclusion: </strong>Early recovery from residual renal function was crucial for preserving residual renal function and preventing chronic kidney disease progression after surgery. Understanding the factors influencing residual renal function preservation might lead to the optimization of treatment strategies in current clinical practice.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1554-1566"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Setup Accuracy of a Skin-markerless Positioning Using Surface-guided Radiotherapy in Accelerated Partial Breast Irradiation.","authors":"Ryohei Yamauchi, Fumihiro Tomita, Tomoyuki Masuda, Shinobu Akiyama, Nobue Uchida, Satoshi Ishikura","doi":"10.21873/invivo.13960","DOIUrl":"https://doi.org/10.21873/invivo.13960","url":null,"abstract":"<p><strong>Background/aim: </strong>Accelerated partial breast irradiation (APBI) is an alternative to whole-breast irradiation in early-stage breast cancer. This study evaluated the setup accuracy of a workflow without skin markers that uses surface-guided radiotherapy (SGRT) in conjunction with clip-based alignment in patients undergoing APBI.</p><p><strong>Patients and methods: </strong>This study recruited 35 patients who underwent APBI after breast-conserving surgery. Treatment plans were generated with 30 Gy in five fractions. During the treatment period, patients were positioned using AlignRT, intentionally omitting the skin marks. After the initial setup, the position was verified <i>via</i> daily kV images or cone-beam computed tomography, with matching surgical clips serving as the basis. Translational and rotational shifts were recorded, along with the monitoring-on time by AlignRT.</p><p><strong>Results: </strong>A total of 175 treatment fractions were analyzed. The mean±standard deviation (SD) residual setup error detected <i>via</i> image registration was 0.01±0.18, -0.09±0.22, and -0.04±0.19 cm in the vertical, longitudinal, and lateral axes, respectively. Setup accuracy within 5 mm in all axes was achieved in over 95% of the treatment fractions assessed. During the treatment period, 28% of patients (10 out of 35) maintained position deviations of less than 3 mm in the 3D vector direction. The mean±SD monitoring-on time was 603.3±214.1 s (range=349-1,353 s).</p><p><strong>Conclusion: </strong>The integration of surface-guided radiation therapy and clip alignment effectively achieved accurate and efficient patient positioning; this can serve as an alternative to traditional skin markers in the external beam APBI workflow.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1598-1606"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone Metabolism-related Serum Biomarkers and Nutritional Markers for Bone Fractures in Living-donor Kidney Transplant Recipients.","authors":"Shunta Hori, Mitsuru Tomizawa, Kuniaki Inoue, Tatsuo Yoneda, Kenta Onishi, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Makito Miyake, Kazumasa Torimoto, Nobumichi Tanaka, Kiyohide Fujimoto","doi":"10.21873/invivo.13949","DOIUrl":"https://doi.org/10.21873/invivo.13949","url":null,"abstract":"<p><strong>Background/aim: </strong>The clinical importance of fracture prevention in patients with end-stage renal disease is well-established. We investigated the roles of bone metabolism-related serum biomarkers and nutritional markers for fractures in Japanese living-donor kidney transplant recipients.</p><p><strong>Patients and methods: </strong>We included 204 consecutive patients who underwent kidney transplantation at Nara Medical University between 2003 and 2022 and retrospectively reviewed their medical charts. The cumulative incidence of fractures was investigated by focusing on bone metabolism-related serum biomarkers and nutritional markers, and related markers were explored.</p><p><strong>Results: </strong>The age at surgery in the fracture group was significantly higher than that in the no-fracture group (<i>p</i>=0.018). Patients with fractures had a significantly higher risk of mortality than those without fractures (<i>p</i>=0.0018); cardiovascular mortality was higher in the fracture group than in the non-fracture group (<i>p</i>=0.052). The cumulative incidence of fractures (median follow-up period, 98 months) was 4.6% at 1 year, 8.6% at 2 years, 12.3% at 3 years, and 15.5% at 5 years after transplant. Particularly, patients with a survival index <26.1 had a significantly higher risk of fracture (<i>p</i>=0.014). Serum intact parathyroid hormone level (a bone metabolism-related biomarker) and survival index (a nutritional marker) were independently related to fractures (<i>p</i>=0.046 and <i>p</i>=0.022, respectively).</p><p><strong>Conclusion: </strong>Serum intact parathyroid hormone level and the survival index may play important roles in determining the incidence of fractures in living donor kidney transplant recipients. Identifying patients at high risk of fractures and providing optimal intervention and education may contribute to improved and personalized management strategies.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1492-1504"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}